Sarepta Therapeutics (SRPT) Change in Accured Expenses (2010 - 2026)

Sarepta Therapeutics has reported Change in Accured Expenses for 17 years, with the latest figure at -$3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 138.36% year-over-year to -$3.4 million; the trailing twelve-month figure through Mar 2026 stood at $91.8 million (down 56.77% YoY), and the FY2025 full-year result was $104.3 million, down 5.77% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.4 million, down from $249.6 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $249.6 million in Q4 2025, with the low at -$103.2 million in Q3 2025.
• Average Change in Accured Expenses over 5 years is $18.2 million, with a median of $1.7 million recorded in 2024.
• Year-over-year, Change in Accured Expenses surged 396.97% in 2024 and tumbled 6223.03% in 2025.
• Tracing SRPT's Change in Accured Expenses over 5 years: stood at $12.9 million in 2022, then surged by 374.36% to $61.1 million in 2023, then surged by 103.34% to $124.2 million in 2024, then soared by 100.96% to $249.6 million in 2025, then tumbled by 101.38% to -$3.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.4 million (Q1 2026), $249.6 million (Q4 2025), and -$103.2 million (Q3 2025), per Business Quant data.

Peer Comparison